156 related articles for article (PubMed ID: 33881795)
1. Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019.
Heyward J; Christopher J; Sarkar S; Shin JI; Kalyani RR; Alexander GC
Diabetes Obes Metab; 2021 Aug; 23(8):1843-1850. PubMed ID: 33881795
[TBL] [Abstract][Full Text] [Related]
2. Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom.
Abrahami D; D'Andrea E; Yin H; Kim SC; Paik JM; Wexler D; Azoulay L; Patorno E
Diabetes Obes Metab; 2023 Oct; 25(10):2980-2988. PubMed ID: 37395339
[TBL] [Abstract][Full Text] [Related]
3. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
4. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
5. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
6. National Trends in Diabetes Medication Use in the United States: 2008 to 2015.
Raval AD; Vyas A
J Pharm Pract; 2020 Aug; 33(4):433-442. PubMed ID: 30572757
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme.
Nicolucci A; Charbonnel B; Gomes MB; Khunti K; Kosiborod M; Shestakova MV; Shimomura I; Watada H; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Surmont F; Tang F; Pocock S
Diabetes Obes Metab; 2019 Nov; 21(11):2474-2485. PubMed ID: 31297947
[TBL] [Abstract][Full Text] [Related]
8. Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.
Turner LW; Nartey D; Stafford RS; Singh S; Alexander GC
Diabetes Care; 2014 Apr; 37(4):985-92. PubMed ID: 24198301
[TBL] [Abstract][Full Text] [Related]
9. Dispensation Patterns of Glucose-Lowering Drugs in Newly Diagnosed Type 2 Diabetes: Routine Data Analysis of Insurance Claims in Germany.
Bongaerts B; Kollhorst B; Kuss O; Pigeot I; Rathmann W
Exp Clin Endocrinol Diabetes; 2022 Sep; 130(9):587-595. PubMed ID: 34942670
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care.
Wilkinson S; Williamson E; Pokrajac A; Fogarty D; Stirnadel-Farrant H; Smeeth L; Douglas IJ; Tomlinson LA
Diabetes Obes Metab; 2020 May; 22(5):847-856. PubMed ID: 31957254
[TBL] [Abstract][Full Text] [Related]
11. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes.
Pawaskar M; Bilir SP; Kowal S; Gonzalez C; Rajpathak S; Davies G
Am J Manag Care; 2019 May; 25(5):231-238. PubMed ID: 31120717
[TBL] [Abstract][Full Text] [Related]
13. Trends in add-on medications following metformin monotherapy for type 2 diabetes.
Swart EC; Neilson LM; Munshi KD; Peasah SK; Henderson R; Good CB
J Manag Care Spec Pharm; 2022 Nov; 28(11):1253-1259. PubMed ID: 36282929
[No Abstract] [Full Text] [Related]
14. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy.
Avogaro A; Delgado E; Lingvay I
Diabetes Metab Res Rev; 2018 May; 34(4):e2981. PubMed ID: 29320602
[TBL] [Abstract][Full Text] [Related]
15. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Guthrie RM
Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers.
Yang JY; Wang T; Pate V; Gower EW; Crowley MJ; Buse JB; Stürmer T
Diabetes Obes Metab; 2019 May; 21(5):1223-1236. PubMed ID: 30697897
[TBL] [Abstract][Full Text] [Related]
17. Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: An Open-Cohort Study of ∼130,000 Swedish Subjects over 14 Years.
Secnik J; Xu H; Schwertner E; Hammar N; Alvarsson M; Winblad B; Eriksdotter M; Garcia-Ptacek S; Religa D
J Alzheimers Dis; 2020; 76(4):1581-1594. PubMed ID: 32741836
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of DPP-4 inhibitors and SGLT2 inhibitors compared to sulphonylureas in adult patients with diabetes with low c-peptide levels with or without anti-GAD65 antibody positivity.
Sudan A; Kalra A; Mirza AA; Kant R
Diabetes Metab Syndr; 2021; 15(4):102197. PubMed ID: 34245964
[TBL] [Abstract][Full Text] [Related]
19. Use of antidiabetic drugs in the U.S., 2003-2012.
Hampp C; Borders-Hemphill V; Moeny DG; Wysowski DK
Diabetes Care; 2014; 37(5):1367-74. PubMed ID: 24623020
[TBL] [Abstract][Full Text] [Related]
20. Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy.
Cesta CE; Rotem R; Bateman BT; Chodick G; Cohen JM; Furu K; Gissler M; Huybrechts KF; Kjerpeseth LJ; Leinonen MK; Pazzagli L; Zoega H; Seely EW; Patorno E; Hernández-Díaz S
JAMA Intern Med; 2024 Feb; 184(2):144-152. PubMed ID: 38079178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
